mAbxience and HP Collaborate on Innovative AI Solutions in Biomanufacturing
In a groundbreaking partnership, mAbxience, a subsidiary of Fresenius, has joined forces with technology giant HP Inc. to leverage artificial intelligence (AI) in the biomanufacturing space. This announcement, made on December 4, 2025, highlights a revolutionary initiative aimed at optimizing the production processes for monoclonal antibodies and biosimilars.
The project involves the creation of a digital twin of biological manufacturing processes. This innovative approach not only seeks to enhance production predictability and consistency but also aims to streamline efficiency. Sergio Martínez, the project’s Technical Lead at HP, emphasized the transformative nature of this partnership, stressing that the use of AI is not solely about process optimization but also about improving patient access to vital treatments.
mAbxience's integration of AI technologies represents a significant advancement in its operational framework. By adopting these cutting-edge solutions, the company seeks to optimize its development strategies for biologic drugs extensively, which would reinforce its standing as a reliable and cost-effective global partner in biomanufacturing.
Timo Liebig, Chief Innovation Officer at mAbxience, commented on the untapped potential AI holds for optimizing biomanufacturing. The collaboration with HP has already resulted in the development of a prototype that enhances the efficiency and management of manufacturing operations. This initial success serves as a testament to how technological innovations can lead to better access for patients needing essential biologic therapies.
The AI-driven development was based on real production data analyzed through sophisticated neural network models and subsequently validated in practical industrial settings. This newly developed tool enables mAbxience’s teams to simulate, analyze, and refine various stages of the cell culture manufacturing process. The core objective is to increase production yields while minimizing process variability, marking a significant leap forward in biomanufacturing capabilities.
As part of a broader strategic collaboration framework, this initiative sets a precedent for future projects aimed at applying AI across numerous critical areas within mAbxience, enhancing productivity, quality, and sustainability across global operations. The solution, initially designed and tested in León, is also expected to be implemented in other mAbxience facilities worldwide, optimizing their overall production processes.
In conclusion, the partnership between mAbxience and HP Inc. showcases an exciting new frontier in biomanufacturing through AI. As both companies work together towards refining these technologies, they expect to not only revolutionize their internal processes but also provide faster and improved access to high-quality biologic products for patients in need. This collaboration encapsulates the essence of innovation in the biotechnology industry, portraying technology as a means to achieve greater healthcare outcomes.
The project involves the creation of a digital twin of biological manufacturing processes. This innovative approach not only seeks to enhance production predictability and consistency but also aims to streamline efficiency. Sergio Martínez, the project’s Technical Lead at HP, emphasized the transformative nature of this partnership, stressing that the use of AI is not solely about process optimization but also about improving patient access to vital treatments.
mAbxience's integration of AI technologies represents a significant advancement in its operational framework. By adopting these cutting-edge solutions, the company seeks to optimize its development strategies for biologic drugs extensively, which would reinforce its standing as a reliable and cost-effective global partner in biomanufacturing.
Timo Liebig, Chief Innovation Officer at mAbxience, commented on the untapped potential AI holds for optimizing biomanufacturing. The collaboration with HP has already resulted in the development of a prototype that enhances the efficiency and management of manufacturing operations. This initial success serves as a testament to how technological innovations can lead to better access for patients needing essential biologic therapies.
The AI-driven development was based on real production data analyzed through sophisticated neural network models and subsequently validated in practical industrial settings. This newly developed tool enables mAbxience’s teams to simulate, analyze, and refine various stages of the cell culture manufacturing process. The core objective is to increase production yields while minimizing process variability, marking a significant leap forward in biomanufacturing capabilities.
As part of a broader strategic collaboration framework, this initiative sets a precedent for future projects aimed at applying AI across numerous critical areas within mAbxience, enhancing productivity, quality, and sustainability across global operations. The solution, initially designed and tested in León, is also expected to be implemented in other mAbxience facilities worldwide, optimizing their overall production processes.
In conclusion, the partnership between mAbxience and HP Inc. showcases an exciting new frontier in biomanufacturing through AI. As both companies work together towards refining these technologies, they expect to not only revolutionize their internal processes but also provide faster and improved access to high-quality biologic products for patients in need. This collaboration encapsulates the essence of innovation in the biotechnology industry, portraying technology as a means to achieve greater healthcare outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.